CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Han, Tae H

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. [electronic resource] - Journal of clinical pharmacology Aug 2013 - 866-77 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1552-4604

10.1002/jcph.116 doi


Adolescent
Adult
Aged
Antineoplastic Agents--administration & dosage
Brentuximab Vedotin
Cross-Over Studies
Cytochrome P-450 CYP3A--metabolism
Cytochrome P-450 CYP3A Inhibitors
Drug Interactions
Feces--chemistry
Female
Hematologic Neoplasms--metabolism
Humans
Immunoconjugates--administration & dosage
Ketoconazole--administration & dosage
Ki-1 Antigen--immunology
Male
Midazolam--administration & dosage
Middle Aged
Oligopeptides--metabolism
Rifampin--administration & dosage
Young Adult